Table 4 Selected immunotherapy trials in advanced SCLC
From: The next generation of immunotherapy: keeping lung cancer in check
Trial name | Phase | Therapy | mOS | 1-year OS | DOR | mPFS | 1-year PFS | mORR (%) | Ref |
 NCT01450761 | 3 | Ipilimumab | 11 | NR | NR | 4.6 | NR | NR | [61] |
PT-DC | 10.9 | NR | NR | 4.4 | NR | NR | Â | ||
 CheckMate 032 | 1/2 | NIVO3 | NR | NR | NR | NR | NR | 10 | [37] |
NIVO1 + IPI1 | NR | NR | NR | NR | NR | 33 |  | ||
NIVO1 + IPI3 | NR | NR | NR | NR | NR | 23 |  | ||
NIVO3 + IPI1 | NR | NR | NR | NR | NR | 19 |  | ||
Ongoing trial name | Phase | Therapy | Setting | Endpoints (starting with primary) | |||||
 CheckMate 331 | 3 | NIVO | Advanced SCLC | OS, PFS, ORR | [36] | ||||
 CheckMate 451 | 3 | NIVO versus NIVO + IPI | Advanced SCLC | OS, PFS | [38] | ||||
 KEYNOTE-028 | 1b | PEMBROQ2W | Advanced SCLC | ORR, PFS, OS, DOR | [39] | ||||
 IMpower 133 | 3 | PT-DC +/-ATEZO | Advanced SCLC | OS, PFS, DOR, safety | [62] | ||||